Ceribell Monitoring for Delirium

(DOM Trial)

This trial tests a new system called the Ceribell Delirium Monitoring System to determine its effectiveness in detecting delirium in ICU patients. Delirium is a serious confusion and mental state that can occur suddenly in critically ill individuals. In this study, some patients will have their brain activity monitored continuously to assess whether this system can better identify and help manage delirium. Suitable candidates for this trial include those admitted to the ICU with serious conditions like sepsis or respiratory failure. As an unphased trial, this study offers patients the chance to contribute to groundbreaking research that could enhance delirium detection and management in critical care settings.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Research has shown that the Ceribell Delirium Monitoring System is safe for use. The FDA has approved it, confirming it meets safety standards. Studies demonstrate its effectiveness in detecting delirium, a state of confusion, by monitoring brain waves. Specifically, research involving 225 patients confirmed the system's accurate detection of delirium. These findings indicate that the Ceribell system is generally well-tolerated, with no major side effects reported.¹²³⁴⁵

Researchers are excited about the Ceribell Delirium Monitoring System because it offers a new way to detect and manage delirium in ICU patients. Unlike current methods that rely on sporadic assessments, this system uses continuous EEG monitoring, providing real-time data to identify delirium more quickly and accurately. This continuous monitoring allows healthcare teams to receive Delirium Trend Reports, which can lead to more informed and timely decisions during patient care. The hope is that the system will catch delirium earlier than traditional methods, potentially improving patient outcomes and reducing the duration of ICU stays.

Research has shown that the Ceribell Delirium Monitoring System effectively detects delirium in ICU patients. In this trial, participants in the prospective Ceribell Delirium Monitoring arm will undergo continuous EEG monitoring with the Ceribell system. This system uses EEG, a test that measures brain activity, to identify delirium more quickly than traditional bedside checks. Studies have found that using Ceribell can improve neurological outcomes by 18% and reduce ICU stays by 4.1 days. The FDA has cleared the system, indicating it has been reviewed and approved for safety and effectiveness. Overall, these findings suggest that Ceribell can enhance the detection and management of delirium in critically ill patients.¹²³⁵⁶